A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal. The clinical ...
Jul 14, 2026
0
4
People with anorexia nervosa have unusually high levels of a hormone called LEAP2 in their blood when they are in the acute phase of the disorder, according to research presented at the Federation of European Neuroscience ...
Jul 9, 2026
0
4
Acupuncture to the ear may help lessen pain from migraines and their impact on daily life, according to new research presented today (Friday) at the Federation of European Neuroscience Societies (FENS) Forum 2026.
Jul 9, 2026
0
4
New research from VCU Massey Comprehensive Cancer Center provides evidence for a combination treatment strategy that uses cells' waste-removal functions to target multiple myeloma. The findings, published recently in Cell ...
Jul 14, 2026
0
4
New research from the University of Mississippi indicates that athletes with ADHD need even more scrutiny when head injuries are involved.
Jul 13, 2026
0
4
A small pilot study from the Center for Psychedelic Research at Imperial College London indicates that psilocybin—the active ingredient in psychedelic "magic mushrooms"—may have potential as a treatment for anorexia nervosa ...
Jul 9, 2026
0
4
Scientists can use patient-derived tissue samples to grow miniature versions of human organs, allowing them to test new medications and disease treatments for personalized care.
Jul 13, 2026
0
4
Exhaustion, trauma and the harsh realities of parenting are driving more Australian families to think twice about having another child.
Jul 8, 2026
0
4
A 0.5% alcohol-based chlorhexidine antiseptic, combined with the natural organic compounds eugenol and menthol, can eliminate 99.9% of Candida parapsilosis cells. This fungus is one of the leading causes of infections in ...
Jul 8, 2026
0
4
For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology.
Jul 9, 2026
0
4
